Multiple Therapeutic Applications of Metformin Moving Beyond Its Anti-Diabetic Role:
A Systematic Review
DOI:
https://doi.org/10.15605/jafes.040.02.10Keywords:
multiple therapeutic uses, metformin, cancer, obesity, cardiovascular disease, anti-aging effectAbstract
Introduction. Introduction. Metformin is a commonly used anti-diabetic drug due to its safety, low cost, and strong glucose-lowering effects. Recent research studies have identified novel molecular targets and pathways for metformin, thereby expanding its potential beyond the treatment of Type 2 diabetes.
Methodology. This systematic review provides the latest updates on the therapeutic applications of metformin in multiple diseases. This systematic review follows the PRISMA guidelines, focusing on experimental studies systematic reviews and meta-analyses from PubMed, Scopus, Web of Science and Google scholar, the search terms ("Metformin"[MeSH] OR "Metformin") AND ("Cancer" OR "Cardiovascular Disease" OR "Neurodegenerative Disease" OR "Aging") AND
("Therapeutic Use" OR "Non-diabetic"). A comprehensive search yielded numerous studies, from which relevant and u-pto-date papers were carefully selected.
Results. The review highlights the multifaceted applications of metformin in various diseases. Evidence demonstrates its positive effects on cardiovascular diseases, obesity, different types of cancer, and liver and kidney disorders. These findings suggest that metformin acts through diverse molecular mechanisms, exerting benefits that extend beyond glycemic control.
Conclusion. Based on the current literature, metformin exhibits a broad spectrum of therapeutic benefits, extending beyond its primary use in diabetes management. Its role in treating multiple diseases has marked it as a multifaceted
agent in modern medicine. Further research is warranted to fully explore its capabilities and optimize its use in different
clinical settings.
Downloads
References
1. Abbasi M, Heath B, McGinness L. Advances in metformin‐delivery systems for diabetes and obesity management. Diabetes Obes Metab. 2024;26(9):3512-29. https://pubmed.ncbi.nlm.nih.gov/38984380 https://doi.org/10.1111/dom.15759
2. Adi S, Tjokroprawiro A. Metformin: Effects Beyond Glycemic Control. In: Proceedings of Surabaya International Physiology Seminar (SIPS). Vol 1. Jawa Timur, Indonesia. 2017;1:349-55. https://doi.org/10.5220/0007339003490355
3. Hasanvand A. The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: A new perspective for treatment and prevention of diseases. Inflammopharmacology. 2022;0(3):775-88. https://pubmed.ncbi.nlm.nih.gov/35419709 https://pmc.ncbi.nlm.nih.gov/articles/PMC9007580 https://doi.org/10.1007/s10787-022-00980-6
4. Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, Sampaio F, Gama V, Leite-Moreira A. Novel therapeutic targets of metformin: Metabolic syndrome and cardiovascular disease. Expert Opin Ther Targets. 2015;19(7):869-77. https://pubmed.ncbi.nlm.nih.gov/25762117 https://doi.org/10.1517/14728222.2015.1025051
5. Jin X, Qiu T, Li L, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13(6):2403-24. https://pubmed.ncbi.nlm.nih.gov/37425065 https://pmc.ncbi.nlm.nih.gov/articles/PMC10326265 https://doi.org/10.1016/j.apsb.2023.01.012
6. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542-6. https://pubmed.ncbi.nlm.nih.gov/24847880 https://pmc.ncbi.nlm.nih.gov/articles/PMC4074244 https://doi.org/10.1038/nature13270
7. Agius L, Ford BE, Chachra SS. The metformin mechanism on gluconeogenesis and AMPK activation: The metabolite perspective. Int J Mol Sci. 2020;21(9):3240. PMID: 32375255 https://pmc.ncbi.nlm.nih.gov/articles/PMC7247334 https://doi.org/10.3390/ijms21093240
8. Ziqubu K, Mazibuko-Mbeje SE, Mthembu SXH, et al. Anti-obesity effects of metformin: A scoping review evaluating the feasibility of brown adipose tissue as a therapeutic target. 2023;24(3):2227. https://pubmed.ncbi.nlm.nih.gov/36768561 https://pmc.ncbi.nlm.nih.gov/articles/PMC9917329 https://doi.org/10.3390/ijms24032227
9. Karise I, Bargut TC, del Sol M, Aguila MB, Mandarim-de-Lacerda CA. Metformin enhances mitochondrial biogenesis and thermogenesis in brown adipocytes of mice. Biomed Pharmacother. 2019;111:1156-65. https://pubmed.ncbi.nlm.nih.gov/30841429 https://doi.org/10.1016/j.biopha.2019.01.021
10. Wei XL, Tao MH, Li RH, Ge SH, Xiao W. Metformin and adipose tissue: A multifaceted regulator in metabolism, inflammation, and regeneration. Endocrinol Metab (Seoul). 2025;40(4):523-38. https://pubmed.ncbi.nlm.nih.gov/40775736 https://pmc.ncbi.nlm.nih.gov/articles/PMC12409170 https://doi.org/10.3803/EnM.2025.2371
11. Niu X, Wang Y, Huang L, et al. Effect of oral metformin on gut microbiota characteristics and metabolite fractions in normal-weight type 2 diabetic mellitus patients. Front Endocrinol (Lausanne). 2024;15:1397034. https://pubmed.ncbi.nlm.nih.gov/39257903 https://pmc.ncbi.nlm.nih.gov/articles/PMC11385314 https://doi.org/10.3389/fendo.2024.1397034
12. Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann TRansl Med. 2014;2(6):56.
https://pubmed.ncbi.nlm.nih.gov/25333031 https://pmc.ncbi.nlm.nih.gov/articles/ PMC4200666 https://doi.org/10.3978/j.issn.2305-5839.2014.04.15
13. Sever MJ, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451-9. https://pubmed.ncbi.nlm.nih.gov/24362411 https://pmc.ncbi.nlm.nih.gov/articles/PMC3922503 https://doi.org/10.1530/EJE-13-0797
14. Feng P, Yu D, Chen L, et al. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacol Sin. 2015;36(2):200-8. https://pubmed.ncbi.nlm.nih.gov/ 25619391 https://pmc.ncbi.nlm.nih.gov/articles/PMC4326793 https://doi.org/10.1038/aps.2014.136
15. Nylander M, Frøssing S, Kistorp C, Faber J, Skouby SO. Liraglutide in polycystic ovary syndrome: A randomized trial, investigating effects on thrombogenic potential. Endocr Connect. 2017;6(2):89-99. https://pubmed.ncbi.nlm.nih.gov/28119323 https://pmc.ncbi.nlm.nih.gov/articles/PMC5424770 https://doi.org/10.1530/EC-16-0113
16. Kesavan S, Chaudhry GS, Akim AM, Ranneh YK. The efficacy of metformin and exenatide in polycystic ovary syndrome (PCOS) patients. Ars Pharm (Online). 2023;64(2):100-22. https://doi.org/10.30827/ars.v64i2.27302
17. Ling J, Wang T, Huang W, et al. Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis. Diabetes, Obes Metab. 2025;27(11):6139-53. https://pubmed.ncbi.nlm.nih.gov/40855964 https://pmc.ncbi.nlm.nih.gov/articles/PMC12515772 https://doi.org/10.1111/dom.70028
18. Jensterle M, Kravos NA, Goričar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: Randomized trial. BMC Endocr Disord. 2017;17(1):5. https://pubmed.ncbi.nlm.nih.gov/ 28143456 https://pmc.ncbi.nlm.nih.gov/articles/PMC5286837 https://doi.org/10.1186/s12902-017-0155-9
19. Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: A pilot randomized study. J Ovarian Res. 2015;8:32. https://pubmed.ncbi.nlm.nih.gov/26032655 https://pmc.ncbi.nlm.nih.gov/articles/PMC4506413 https://doi.org/10.1186/s13048-015-0161-3
20. Salamun V, Jensterle M, Janez A, Bokal EV. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: A pilot randomized study. European Journal of Endocrinology. 2018;179(1):1-11. https://pubmed.ncbi.nlm.nih.gov/29703793 https://doi.org/10.1530/EJE-18-0175
21. Chomanicova N, Gazova A, Adamickova A, Valaskova S, Kyselovic J. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin. Physiol Res.2021;70(4):501-8. https://pubmed.ncbi.nlm.nih.gov/34062070 https://pmc.ncbi.nlm.nih.gov/articles/PMC8820546 https://doi.org/10.33549/physiolres.934618
22. Shao F, Li Y, Zhao Y. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: A meta-analysis. Front Endocrinol (Lausanne). 2023;14:1139858. https://pubmed.ncbi.nlm.nih.gov/37415671 https://pmc.ncbi.nlm.nih.gov/articles/PMC10320576 https://doi.org/10.3389/fendo.2023.1139858
23. Janda M, Robledo KP, Gebski V, et al. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecol Oncoly. 2021;161(1):143-51. https://pubmed.ncbi.nlm.nih.gov/33762086 https://doi.org/10.1016/j.ygyno.2021.01.029
24. Acosta-Torres S, Murdock T, Matsuno R, et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates. Gynecologic Oncology. 2020;157(2):348-56. https://pubmed.ncbi.nlm.nih.gov/32085863 https://doi.org/10.1016/j.ygyno.2020.02.008
25. Mandelbaum RS, Ciccone MA, Nusbaum DJ, et al. Progestin therapy for obese women with complex atypical hyperplasia: Levonorgestrel-releasing intrauterine device vs systemic therapy. American journal of obstetrics and gynecology. 2020;223(1):103.e1-13. https://pubmed.ncbi.nlm.nih.gov/31978437 https://pmc.ncbi.nlm.nih.gov/articles/PMC7751571 https://doi.org/10.1016/j.ajog.2019.12.273
26. Factor PAA, Pasamba KC. Metformin as an adjunct to progestin therapy in endometrial hyperplasia and early-stage endometrial cancer: A systematic review and meta-analysis of randomized controlled trials. Acta Medica Philipp. 2024;58(11)-62-71. https://pubmed.ncbi.nlm.nih.gov/39006985 https://pmc.ncbi.nlm.nih.gov/articles/PMC11239990 https://doi.org/10.47895/amp.v58i11.8155
27. Yuan F, Hu Y, Han X, Li Q. Metformin in combination with progesterone improves the pregnancy rate for patients with early endometrial cancer. 2022;2022:1961016. https://pubmed.ncbi.nlm.nih.gov/35854762 https://pmc.ncbi.nlm.nih.gov/articles/PMC9279044 https://doi.org/10.1155/2022/1961016
28. Adamyan L, Pivazyan L, Isaeva S, Shapovalenko R, Zakaryan A. Metformin and progestins in women with atypical hyperplasia or endometrial cancer: Systematic review and meta-analysis. Arch Gynecol Obst. 2024;309(6):2289-305. https://pubmed.ncbi.nlm.nih.gov/38503850 https://doi.org/10.1007/s00404-024-07416-2
29. Shiwani H, Clement NS, Daniels JP, Atiomo W. Metformin for endometrial hyperplasia. Cochrane Database Sy Rev. 2024;2024(5):CD012214. https://pubmed.ncbi.nlm.nih.gov/38695827 https://pmc.ncbi.nlm.nih.gov/articles/PMC11064888 https://doi.org/10.1002/14651858.CD012214.pub3
30. Mitsuhashi A, Habu Y, Kobayashi T, et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol. 2019;30(6):e90. https://pubmed.ncbi.nlm.nih.gov/31576686 https://pmc.ncbi.nlm.nih.gov/articles/PMC6779615 https://doi.org/10.3802/jgo.2019.30.e90
31. Bu Y, Peng M, Tang X, et al. Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK ‐dependent mechanisms. Journal of Cellular and Molecular Medicine. 2022;26(19):4886-903. https://pubmed.ncbi.nlm.nih.gov/36052760 https://pmc.ncbi.nlm.nih.gov/articles/PMC9549498 https://doi.org/10.1111/jcmm.17519
32. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction. 2003;41(9):1510-8. https://pubmed.ncbi.nlm.nih.gov/12742291 https://doi.org/10.1016/s0735-1097(03)00185-2
33. Lupón J, Bayes-Genis A. Left ventricular ejection fraction in heart failure. Eur Cardiol. 2018;13(2):91-2. https://pubmed.ncbi.nlm.nih.gov/30697350 https://pmc.ncbi.nlm.nih.gov/articles/PMC6331760 https://doi.org/10.15420/ecr.2018.13.2.GE1
34. Xiao J, Wu H, Gao Z, Wei H, Huang W. Association of left ventricular ejection fraction with risk of cardiovascular diseases: A prospective cohort study. Sci Rep. 2024;14(1):25233. https://pubmed.ncbi.nlm.nih.gov/39448744 https://pmc.ncbi.nlm.nih.gov/articles/PMC11502777 https://doi.org/10.1038/s41598-024-76462-2
35. Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993;72(9):672-6. https://pubmed.ncbi.nlm.nih.gov/8249843 https://doi.org/10.1016/0002-9149(93)90883-e
36. Ohno M, Segawa T, Noda T, Yasuda Y, Yamamoto J. Retrospective comparison of left ventricular systolic dysfunction assessed by left ventricular global longitudinal strain in hemodialysis patients with preserved left ventricular ejection fraction and patients with hypertensive left ventricular hypertrophy. BMC Nephrol. 2025;26(1):425. https://pubmed.ncbi.nlm.nih.gov/40745596 https://pmc.ncbi.nlm.nih.gov/articles/PMC12312339 https://doi.org/10.1186/s12882-025-04368-w
37. Veldman BAJ, Wijn AM, Knoers N, Praamstra P, Horstink MWIM. Genetic and environmental risk factors in Parkinson’s disease. Clin Neurol Neurosurg. 1998;100(1):15-26. https://pubmed.ncbi.nlm.nih.gov/9637199 https://doi.org/10.1016/s0303-8467(98)00009-2
38. Ball N, Teo WP, Chandra S, Chapman J. Parkinson’s Disease and the environment. Front Neurol. 2019;10(218). https://pubmed.ncbi.nlm.nih.gov/30941085 https://pmc.ncbi.nlm.nih.gov/articles/PMC6433887 https://doi.org/10.3389/fneur.2019.00218
39. Tahmi M, Luchsinger JA. Metformin in the prevention of Alzheimer’s disease and Alzheimer’s disease related dementias. J Prev Alzheimers Dis. 2023;10(4):706-17. https://pubmed.ncbi.nlm.nih.gov/37874091 https://doi.org/10.14283/jpad.2023.113
40. Chen S, Gan D, Lin S, et al. Metformin in aging and aging-related diseases: Clinical applications and relevant mechanisms. Theranostics. 2022;12(6):2722-40. https://pubmed.ncbi.nlm.nih.gov/35401820 https://pmc.ncbi.nlm.nih.gov/articles/PMC8965502 https://doi.org/10.7150/thno.71360
41. Wang L, Hu Z, Chen H, Zhou C, Hu X. Prevalence of mild cognitive impairment and its association with malnutrition in older Chinese adults in the community. Front Public Health. 2024;12:1407694. https://pubmed.ncbi.nlm.nih.gov/39206002 https://pmc.ncbi.nlm.nih.gov/articles/PMC11353079 https://doi.org/10.3389/fpubh.2024.1407694
42. Laurie-Anne Boivin-Proulx, Brouillette J, Dorais M, Perreault S. Association between cardiovascular diseases and dementia among various age groups: A population-based cohort study in older adults. Sci Rep. 2023;13(1):14881. https://pubmed.ncbi.nlm.nih.gov/37689801 https://pmc.ncbi.nlm.nih.gov/articles/PMC10492794 https://doi.org/10.1038/s41598-023-42071-8
43. Fang C, Lv L, Mao S, Dong H, Liu B. Cognition deficits in Parkinson’s disease: Mechanisms and treatment. Parkinson’s Dis. 2020;2020:2076942. https://pubmed.ncbi.nlm.nih.gov/32269747 https://pmc.ncbi.nlm.nih.gov/articles/PMC7128056 https://doi.org/10.1155/2020/2076942
44. Villani S, Ferraro OE, Poloni TE, Guaita A. Dementia and risk factors: Results from a prospective, population-based cohort study. Life (Basel). 2022;12(7):1055. https://pubmed.ncbi.nlm.nih.gov/35888143 https://pmc.ncbi.nlm.nih.gov/articles/PMC9315866 https://doi.org/10.3390/life12071055
45. Garcia-Ptacek S, Kramberger MG. Parkinson disease and dementia. J Geriatr Psychiatry Neurol. 2016;29(5):261-70. https://pubmed.ncbi.nlm.nih.gov/27502301 https://doi.org/10.1177/0891988716654985
46. Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol. 2003;2(4):229-37. https://pubmed.ncbi.nlm.nih.gov/12849211 https://doi.org/10.1016/s1474-4422(03)00351-x
47. Canet J, Raeder J, Rasmussen LS, et al; ISPOCD2 investigators. Cognitive dysfunction after minor surgery in the elderly. Acta Anaesthesiol Scand. 2003;47(10):1204-10. https://pubmed.ncbi.nlm.nih.gov/14616316 https://doi.org/10.1046/j.1399-6576.2003.00238.x
48. Armstrong R. Risk factors for Alzheimer’s Disease. Folia Neuropathol. 2019;57(2):87-105. https://pubmed.ncbi.nlm.nih.gov/31556570 https://doi.org/10.5114/fn.2019.85929
49. Gorelick PB. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci. 2010;1207(1):155-62. https://pubmed.ncbi.nlm.nih.gov/20955439 https://doi.org/10.1111/j.1749-6632.2010.05726.x
50. Bamford A, Henderson EJ. Parkinson’s disease in older people. Medicine. 2021;49(1):56-61. https://doi.org/10.1016/j.mpmed.2020.10.008
51. Connor J. Diagnosis and management of dementia in older people. Medicine. 2020;49(1):22-5. https://doi.org/10.1016/j.mpmed.2020.10.005
52. Ruan X, Li H, Wang Z, et al. The influencing factors of cognitive impairment in elderly individuals in Chengdu city: A cross-sectional study based on AD8. BMC Geriatr. 2025;25(1):19. https://pubmed.ncbi.nlm.nih.gov/39789427 https://pmc.ncbi.nlm.nih.gov/articles/PMC11715083 https://doi.org/10.1186/s12877-024-05661-3
53. Alšauskė SV, Grabauskytė I, Liseckienė I, Macijauskienė J. Assessment of cognitive functions in multimorbid patients in Lithuanian primary care settings: A cross-sectional study using MMSE and LT-GPCOG. Medicina (Kaunas). 2025;61(1):122. https://pubmed.ncbi.nlm.nih.gov/39859104 https://pmc.ncbi.nlm.nih.gov/articles/PMC11766642 https://doi.org/10.3390/medicina61010122
54. Ordoobadi AJ, Dhanani H, Tulebaev SR, Salim A, Cooper Z, Jarman MP. Risk of dementia diagnosis after injurious falls in older adults. JAMA Netw Open. 2024;7(9):e2436606. https://pubmed.ncbi.nlm.nih.gov/39348117 https://pmc.ncbi.nlm.nih.gov/articles/PMC11443352 https://doi.org/10.1001/jamanetworkopen.2024.36606
55. Negru DC, Tit DM, Negru PA, Bungau G, Marin RC. Predictors of cognitive decline in Alzheimer’s disease: A longitudinal Bayesian analysis. Medicina (Kaunas). 2025;61(5):877. https://pubmed.ncbi.nlm.nih.gov/40428835 https://pmc.ncbi.nlm.nih.gov/articles/PMC12113534 https://doi.org/10.3390/medicina61050877
56. Friedman TW, Yelland GW, Robinson SR. Subtle cognitive impairment in elders with Mini-Mental State Examination scores within the “normal” range. Int J Geriatr Psychiatry. 2011;27(5):463-71. https://pubmed.ncbi.nlm.nih.gov/21626569 https://doi.org/10.1002/gps.2736
57. Riedel-Heller SG, Busse A, Aurich C, Matschinger H, Angermeyer MC. Prevalence of dementia according to DSM–III–R and ICD–10. Br J Psychiatry. 2001;179(3):250-4. https://pubmed.ncbi.nlm.nih.gov/11532803 https://doi.org/10.1192/bjp.179.3.250
58. Du XL, Song L. A large retrospective cohort study on the risk of Alzheimer’s disease and related dementias in association with vascular diseases and cancer therapy in men with prostate cancer. J Prev Alzheimers Dis. 2023;10(2):193-206. https://pubmed.ncbi.nlm.nih.gov/36946446 https://pmc.ncbi.nlm.nih.gov/articles/PMC10709824 https://doi.org/10.14283/jpad.2023.8
59. Hsiao FY, Peng LN, Wen YW, Liang CK, Wang PN, Chen LK. Care needs and clinical outcomes of older people with dementia: A population-based propensity score-matched cohort study. PLoS One. 2015;10(5):e0124973. https://pubmed.ncbi.nlm.nih.gov/25955163 https://pmc.ncbi.nlm.nih.gov/articles/PMC4425532 https://doi.org/10.1371/journal.pone.0124973
60. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2012;1(1):57-64. https://pubmed.ncbi.nlm.nih.gov/24648894 https://pmc.ncbi.nlm.nih.gov/articles/PMC3956897 https://doi.org/10.3892/br.2012.18
61. Mazza AD, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:1-13. https://pubmed.ncbi.nlm.nih.gov/ 22194737 https://pmc.ncbi.nlm.nih.gov/articles/PMC3238361 https://doi.org/10.1155/2012/716404
62. Huang Y, Wang X, Yan C, et al. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022;101(43):e31437. https://pubmed.ncbi.nlm.nih.gov/36316840 https://pmc.ncbi.nlm.nih.gov/articles/PMC9622616 https://doi.org/10.1097/MD.0000000000031437
63. Brackett CC. Clarifying metformin’s role and risks in liver dysfunction. J Am Pharm Assoc (2003). 2010;50(3):407-10. https://pubmed.ncbi.nlm.nih.gov/20452916 https://doi.org/10.1331/JAPhA.2010.08090
64. Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: Insights from the cellular to patient levels. Gut Liver. 2021;15(6):827-40. https://pubmed.ncbi.nlm.nih.gov/ 33820884 https://pmc.ncbi.nlm.nih.gov/articles/PMC8593497 https://doi.org/10.5009/gnl20367
65. Federica Perazza, Leoni L, Colosimo S, et al. Metformin and the liver: Unlocking the full therapeutic potential. Metabolites. 2024;14(4):186. https://pubmed.ncbi.nlm.nih.gov/38668314 https://pmc.ncbi.nlm.nih.gov/articles/PMC11052067 https://doi.org/10.3390/metabo14040186
66. Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: Insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28(2):200-8. https://pubmed.ncbi.nlm.nih.gov/18445142 https://doi.org/10.1111/j.1365-2036.2008.03723.x
67. Ramanathan R, Ali AH, Ibdah JA. Mitochondrial dysfunction plays central role in nonalcoholic fatty liver disease. Int J Mol Sci. 2022;23(13):7280. https://pubmed.ncbi.nlm.nih.gov/35806284 https://pmc.ncbi.nlm.nih.gov/articles/PMC9267060 https://doi.org/10.3390/ijms23137280
68. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol. 2008;46(2):113-8. https://pubmed.ncbi.nlm.nih.gov/18839053 https://doi.org/10.1007/s00592-008-0067-2
69. Lee BW, Lee Y, Park CY, et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A position statement of the fatty liver research group of the Korean Diabetes Association. Diabetes Metab J. 2020;44(3):382-401. https://pubmed.ncbi.nlm.nih.gov/32431115 https://pmc.ncbi.nlm.nih.gov/articles/ PMC7332334 https://doi.org/10.4093/dmj.2020.0010
70. Woo SL, Xu H, Li H, et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS One. 2014;9(3):e91111. https://pubmed.ncbi.nlm.nih.gov/24638078 https://pmc.ncbi.nlm.nih.gov/articles/PMC3956460 https://doi.org/10.1371/journal.pone.0091111
71. García-Compeán D, Orsi E, Kumar R, et al. Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives. World J Gastroenterol. 2022;28(8):775-93. https://pubmed.ncbi.nlm.nih.gov/35317103 https://pmc.ncbi.nlm.nih.gov/articles/PMC8900578 https://doi.org/10.3748/wjg.v28.i8.775
72. Hesen NA, Riksen NP, Aalders B, et al. A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction. 2017;12(8):e0183664. https://pubmed.ncbi.nlm.nih.gov/28832637 https://pmc.ncbi.nlm.nih.gov/articles/PMC5568412 https://doi.org/10.1371/journal.pone.0183664
73. Mariam Ahmed Galal, Al-Rimawi M, Abdurrahman Hajeer, Dahman H, Samhar Alouch, Aljada A. Metformin: A dual-role player in cancer treatment and prevention. Int J Mol Sci. 2024;25(7):4083. https://pubmed.ncbi.nlm.nih.gov/38612893 https://pmc.ncbi.nlm.nih.gov/articles/PMC11012626 https://doi.org/10.3390/ijms25074083
74. Barnwal N, Dubey S, Tiwari P. Targeting metabolic dysregulation in Alzheimer’s disease: A potential therapeutic strategy. Curr Drug Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/40990282 https://doi.org/10.2174/0113892002408089250912080734
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asif jan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
